Flourish HEC + BioGenesis arm for Infertility

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Dr. Aimee Eyvazzadeh, San Ramon, CA
Infertility+1 More
Flourish HEC and BioGenesis - CombinationProduct
Eligibility
18 - 65
Female
What conditions do you have?
Select

Study Summary

This study intends to address whether improving the vaginal microbiome can help couples increase chances of conceiving.

Eligible Conditions

  • Infertility
  • Unexplained Infertility

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

3 Primary · 5 Secondary · Reporting Duration: 24 months or fewer

15 months
Conception within one year
24 months or fewer
Birthweight at delivery
Gestational age at delivery
Rate of live birth
Rates of pregnancy complications
3 months
Conception at home
Month 3
Change in vaginal microbiome
Change in vaginal pH

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

Control arm
1 of 2
Flourish HEC + BioGenesis arm
1 of 2
Active Control
Experimental Treatment

40 Total Participants · 2 Treatment Groups

Primary Treatment: Flourish HEC + BioGenesis arm · No Placebo Group · Phase 1

Flourish HEC + BioGenesis arm
CombinationProduct
Experimental Group · 1 Intervention: Flourish HEC and BioGenesis · Intervention Types: CombinationProduct
Control armNoIntervention Group · 1 Intervention: Control arm · Intervention Types:

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 24 months or fewer
Closest Location: Dr. Aimee Eyvazzadeh · San Ramon, CA
N/AFirst Recorded Clinical Trial
1 TrialsResearching Infertility
0 CompletedClinical Trials

Eligibility Criteria

Age 18 - 65 · Female Participants · 1 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.